Psoriasis News and Research

Latest Psoriasis News and Research

Scientists identify key molecules that trigger immune system to fight tularemia

Research led by scientists at St. Jude Children's Research Hospital has identified key molecules that trigger the immune system to launch an attack on the bacterium that causes tularemia.

24 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.

21 Mar 2015

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

Basic research on blood pressure has led researchers from Inserm (Inserm Unit 1138, "Cordeliers Research Centre") to obtain unexpected results: drugs used to treat hypertension (high blood pressure) reduce side effects from corticosteroid-based creams used to treat certain skin diseases.

19 Mar 2015

New antibody treatment blocks immune signaling protein crucial to psoriasis

Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report.

16 Mar 2015

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA).

13 Mar 2015

Diplomat Pharmacy selected to distribute Novartis' COSENTYX (secukinumab)

Diplomat Pharmacy, Inc. has been selected to the Novartis limited-distribution panel to distribute COSENTYX (secukinumab), a drug approved in January by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.

4 Mar 2015

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Prime Therapeutics LLC received the Pharmacy Benefit Management Institute's 2015 Rx Innovation Award today in recognition of its innovative "Specialty Drug Watch List."

3 Mar 2015

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets.

1 Mar 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK.

26 Feb 2015

Psoriasis management: an interview with Dr Sandy McBride

A major challenge around treating psoriasis is communication - psoriasis can flare and resolve in between appointments so it can be difficult to express and describe the life impact of these flares and recall possible triggers and response to treatments. People with psoriasis can also find it very difficult to talk about their emotions – something known as alexithymia – again making it difficult for clinicians to fully appreciate the impact of psoriasis.

25 Feb 2015

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western Reserve University dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice.

23 Feb 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.

19 Feb 2015

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis.

17 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by Health Canada.

13 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

Psoriasis News and Research

Latest Psoriasis News and Research

Scientists identify key molecules that trigger immune system to fight tularemia

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Janssen announces acquisition of XO1

Spironolactone drug reduces side effects of corticosteroid-based dermatological creams

New antibody treatment blocks immune signaling protein crucial to psoriasis

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Diplomat Pharmacy selected to distribute Novartis' COSENTYX (secukinumab)

Prime Therapeutics recognized with PBMI's 2015 Rx Innovation Award

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Psoriasis management: an interview with Dr Sandy McBride

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Chemotherapy or immunosuppressive treatment may reactivate HBV

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Psoriasis News and Research

Latest Psoriasis News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in